Treatment of Cheyne-Stokes Respiration in Heart Failure with Adaptive Servo-Ventilation: An Integrative Model

Adv Exp Med Biol. 2022:1384:79-103. doi: 10.1007/978-3-031-06413-5_6.

Abstract

The SERVE-HF (Treatment of Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Patients with Heart Failure) multicenter trial found a small but significant increase in all-cause and cardiovascular mortality in patients assigned to adaptive servo-ventilation (ASV) versus guideline-based medical treatment. To better understand the physiological underpinnings of this clinical outcome, we employ an integrative computer model to simulate congestive heart failure with Cheyne-Stokes respiration (CHF-CSR) in subjects with a broad spectrum of underlying pathogenetic mechanisms, as well as to determine the in silico changes in cardiopulmonary and autonomic physiology resulting from ASV. Our simulation results demonstrate that while the elimination of CSR through ASV can partially restore cardiorespiratory and autonomic physiology toward normality in the vast majority of CHF phenotypes, the degree of restoration can be highly variable, depending on the combination of CHF mechanisms in play. The group with the lowest left ventricular ejection fraction (LVEF) appears to be most vulnerable to the potentially adverse effects of ASV, but the level of pulmonary capillary wedge pressure (PCWP) plays an important role in determining the nature of these effects.

Keywords: Adaptive Servo-Ventilation; Autonomic Regulation; Cheyne-Stokes Respiration; Computer Simulation; Heart Failure; Integrative Physiology; Mathematical Model; Sleep Apnea.

Publication types

  • Multicenter Study

MeSH terms

  • Cheyne-Stokes Respiration / therapy
  • Heart Failure* / complications
  • Heart Failure* / therapy
  • Humans
  • Respiration, Artificial / adverse effects
  • Sleep Apnea, Central* / complications
  • Sleep Apnea, Central* / therapy
  • Stroke Volume
  • Treatment Outcome
  • Ventricular Function, Left / physiology